A Drug That Boosts Both Endocannabinoids Enhanced Morphine's Pain Relief and Reduced Heroin-Seeking Behavior in Mice | Research

The takeaway

The dual FAAH-MAGL inhibitor SA-57 reversed neuropathic and inflammatory pain, enhanced morphine's pain-relieving effects at low doses, and strikingly reduced heroin-seeking behavior in mice.

Readers interested in alternatives to opioids for pain management.

SA-57 enhanced morphine pain relief without side effects AND reduced heroin-seeking behavior

What the researchers found

SA-57, which simultaneously boosts both endocannabinoids (anandamide via FAAH inhibition and 2-AG via MAGL inhibition), produced multiple therapeutically relevant effects in mice.

For pain: SA-57 reversed both neuropathic pain (nerve injury model) and inflammatory pain (carrageenan model). Its anti-pain effects required both CB1 and CB2 receptors, while its anti-swelling effects required only CB2.

For opioid enhancement: Low doses of SA-57 (which elevated anandamide but not 2-AG) significantly augmented morphine's pain-relieving effects without producing THC-like behavioral side effects. This "opioid-sparing" effect could allow lower opioid doses.

For addiction: SA-57 reduced heroin-reinforced nose-poking behavior and lowered the progressive ratio breakpoint (how hard mice would work) for heroin, suggesting it reduced heroin's rewarding properties.

Why it matters

This study addresses two major public health crises simultaneously: chronic pain and opioid addiction. A compound that enhances morphine's pain relief (allowing lower doses) while also reducing the desire for heroin could fundamentally change pain management. The endocannabinoid system is positioned at the intersection of pain and reward, making it a promising therapeutic target.

The numbers in context

SA-57 was more potent at elevating anandamide than 2-AG. Low doses augmented morphine without cannabimimetic side effects. Anti-allodynic effects required CB1 and CB2 receptors. Anti-edematous effects required CB2 only. SA-57 reduced heroin nose-poking and progressive ratio breakpoint.

How the study worked

Chronic constriction injury (CCI) model of neuropathic pain and carrageenan inflammatory pain model in mice. Receptor involvement tested with selective antagonists. Morphine combination experiments for opioid-sparing effects. Heroin self-administration paradigm for addiction-related outcomes.

What this study cannot tell us

Mouse study with acute pain models that may not represent chronic human pain. SA-57 is a research tool compound, not a clinical drug. The heroin self-administration results, while striking, need replication and extension to other opioid paradigms. Long-term safety of dual FAAH-MAGL inhibition is unknown.

How to read the evidence

Preliminary evidence from a comprehensive animal study with multiple pain and addiction models.

When this study was published

Published in 2017. Endocannabinoid-based opioid-sparing approaches are an active area of drug development.

The bigger picture

The opioid crisis has driven urgent search for non-opioid pain treatments and opioid-sparing strategies. Endocannabinoid modulation represents a mechanistically distinct approach that could reduce opioid dosing requirements while also dampening opioid reward signaling. SA-57's dual effects on pain and addiction make it a particularly compelling preclinical candidate.

Questions still open

Would dual FAAH-MAGL inhibition be safe for long-term use in chronic pain patients? Could this approach reduce opioid prescribing in clinical practice? Does the anti-heroin effect translate to reduced opioid relapse?

Common questions

Could boosting endocannabinoids replace opioids for pain?

This study suggests endocannabinoid enhancement (via SA-57) can relieve pain on its own and amplify morphine's effects at lower doses. However, this was a mouse study using a research compound. Whether this approach will be effective and safe in humans remains to be determined through clinical development.

How could the same compound help with both pain and addiction?

The endocannabinoid system modulates both pain processing and reward circuitry. SA-57 boosted endocannabinoid levels, which reduced pain signaling while also diminishing the rewarding properties of heroin. This dual action on overlapping brain systems makes endocannabinoid modulation uniquely positioned for opioid-sparing pain management.

Read the original research

The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice.

Neuropharmacology, 114, 156-167

View on PubMed ↗Publisher’s paper ↗

Citation

Wilkerson, Jenny L; Ghosh, Sudeshna; Mustafa, Mohammed; Abdullah, Rehab A; Niphakis, Micah J; Cabrera, Roberto; Maldonado, Rafael L; Cravatt, Benjamin F; Lichtman, Aron H. (2017). The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice.. Neuropharmacology, 114, 156-167. https://doi.org/10.1016/j.neuropharm.2016.11.015